Clinical Protocols

Oncology Division

Oncology Clinical Trials

 

 

Hematology Division

Click on the title of a protocol to view its description in ClinicalTrials.gov.
 

Disease Protocol (Sponsor) Status PI/Contact Comments
Atypical HUS Atypical Hemolytic-Uremic Syndrome (aHUS) Registry Open to enrollment PI: Elaine Majerus
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998
Atypical HUS
Banking Laboratory Studies Blood Acquistion for Investigation of Thrombotic Disorders Open PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
314-362-9998
Thrombosis Banking
Bleeding and clotting disorders CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
314-362-9998
CNL/aCML Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
 
Essential Thrombocythemia A Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea Open PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
No prior treatment with JAK inhibitors or anagrelide
Hemophilia A and B My Life Our Future: Genotyping of Patients with Hemophilia A or B and Tissue Repository Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
314-362-9998
Hemophilia/Bleeding American Thrombosis and Hemostasis Network Data Collection Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
314-362-9998
Myelodysplastic Syndrome A Phase 3 Study of Roxadustat for Anemia in MDS patients Open to enrollment PI: Amy Zhou
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Limited prior ESA use
Myelofibrosis Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
No prior JAKi therapy
Myelofibrosis Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Enrolling by invitation only PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
 
Myelofibrosis Momelotinib in Transfusion-Dependent Adults with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thromocythemia Myelofibrosis (Post-PV/ET MF) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
 
Myelofibrosis A Phase 2 Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Open and Enrolling PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
MF patients with suboptimal response to ruxolitinib
Myelofibrosis A Phase 2 Study of Pacritinib in Patients with Thrombocytopenia and Myelofibrosis Previously Treated with Ruxolitinib Open PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
Prior ruxolitinib treatment failure/intolerance and palpable splenomegaly
Myeloid/Lymphoid Neoplasms A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Open PI: Stephen Oh
Contact: Nicole Gaudin
nrgaudin@wustl.edu
314-747-7960
Patients with 8p11 (FGFR1) rearrangement
PNH Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Open to enrollment PI: Elaine Majerus
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998
PNH Registry
Polycythemia Vera Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kdgordon@wustl.edu
314-362-0156
 
Sickle Cell Disease A Phase II Trial of Regadenoson in Sickle Cell Anemia Open to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
HbSS and S Beta Null
Sickle Cell Disease Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) Ongoing; closed to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
garrett_l@wustl.edu
Hb SS and S Beta Null
Thrombosis ATTRACT Ongoing; closed to enrollment PI: Suresh Vedantham
Contact: Morey Blinder
mblinder@wustl.edu
314-362-9998
New DVT
TTP/microangiopathy Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Open to enrollment PI: Evan Sadler
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998
Low dose Rituximab for TTP